VAC14 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
Alternative names
ArPIKfyve, FLJ10305, FLJ36622, FLJ46582, MGC149815, MGC149816, OTTHUMP00000174908, Protein VAC14 homolog, TAX1BP2, TRX, Tax1 (human T cell leukemia virus type I) binding protein 1, Tax1 (human T cell leukemia virus type I) binding protein 2, Tax1-binding protein 2, VAC14_HUMAN, Vac14 homolog, Vac14 homolog (S. cerevisiae)
What's included?
Recommended products
VAC14 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- VAC14
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VAC14 also known as ArPIKfyve is a regulatory protein with a molecular weight of roughly 100 kDa. It is expressed in various tissues but particularly notable in the brain. Mechanically VAC14 works with FIG4 and PIKFYVE in a complex that regulates the levels of phosphatidylinositol 35-bisphosphate (PI(35)P2) in cells. It interacts directly with PIKFYVE to control its kinase activity which is important for maintaining the balance of phosphoinositides.
- Biological function summary
VAC14 takes an important role in phosphoinositide metabolism and is part of the PIKfyve complex which consists of PIKFYVE and FIG4. This complex regulates the synthesis of PI(35)P2 a lipid second messenger involved in various cellular processes. Through this regulation VAC14 influences membrane trafficking endosome-to-lysosome transport and lysosomal homeostasis. Proper functioning of VAC14 is essential for cellular integrity and response to environmental changes especially in neuronal cells.
- Pathways
VAC14 involves itself in the phosphoinositide signaling pathway and the lysosomal pathway. This protein forms a module with PIKFYVE and FIG4 to control the production of PI(35)P2 which is important for endolysosomal dynamics. VAC14’s activity influences autophagic flux and endosomal maturation processes integral to cellular homeostasis. The modulation of these pathways ensures proper intracellular processing and material degradation which is linked to cellular health and stress responses.
- Associated diseases and disorders
VAC14 has associations with Charcot-Marie-Tooth disease (CMT) and fibrotic lung disease. Mutations affecting VAC14 can lead to the malformation of neuronal axons and defects in both motor and sensory neurons in CMT. In these diseases VAC14 interacts with FIG4 where mutations in either protein can disrupt PI(35)P2 levels leading to neuropathy. Understanding the role of VAC14 in these contexts opens avenues for targeted therapeutic interventions in related neurological and fibrotic disorders.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (ab258756)
Allele-1: 1 bp deletion in exon1
Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (ab258756)
Allele-2: 1 bp insertion in exon1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com